VALIDATION IMAGES
Human HepG2 cells probed with GAPDH(3E12) Polyclonal Antibody, unconjugated (bsm-0978M) at 1:300 overnight at 4°C followed by a conjugated secondary antibody at 1:10000 for 90 minutes at 37°C.
Human A549 cells probed with GAPDH(3E12) Polyclonal Antibody, unconjugated (bsm-0978M) at 1:300 overnight at 4°C followed by a conjugated secondary antibody at 1:10000 for 90 minutes at 37°C.
Lane 1: mouse placenta; Lane 2: 293T cells probed with GAPDH(3E12) Polyclonal Antibody, unconjugated (bsm-0978M) at 1:300 overnight at 4°C followed by a conjugated secondary antibody at 1:10000 for 90 minutes at 37°C.
Lane 1: A549 cell lysates; Lane 2: 293T cell lysates; Lane 3: HepG2 cell lysates; Lane 4: Hela cell lysates probed with GAPDH(3E12) Monoclonal Antibody, Unconjugated (bsm-0978M) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: A549 cell lysates; Lane 2: 293T cell lysates; Lane 3: HepG2 cell lysates; Lane 4: Hela cell lysates probed with GAPDH(3E12) Monoclonal Antibody, Unconjugated (bsm-0978M) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Human Hela cell lysates; Lane 2: Human HUVEC cell lysates; Lane 3: Human A549 cell lysates; Lane 4: Human MCF-7 cell lysates probed with GAPDH Monoclonal Antibody, Unconjugated (bsm-0978M ) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.